Vulnerable plaque imaging using <superscript>18</superscript> F-sodium fluoride positron emission tomography. - OpacWWW

Szczegóły
Abstrakt

Tytuł:: Vulnerable plaque imaging using F-sodium fluoride positron emission tomography.
Autorzy:: Kwiecinski J; Department of Imaging (Division of Nuclear Medicine), Medicine, and Biomedical Sciences, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, USA.; Department of Interventional Cardiology and Angiology, Institute of Cardiology, Alpejska 42, 04-628 Warsaw, Poland.
Slomka PJ; Department of Imaging (Division of Nuclear Medicine), Medicine, and Biomedical Sciences, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, USA.
Dweck MR; BHF Centre for Cardiovascular Science, University of Edinburgh, 49 Little France Crescent, Edinburgh EH16 4SB, UK.
Newby DE; BHF Centre for Cardiovascular Science, University of Edinburgh, 49 Little France Crescent, Edinburgh EH16 4SB, UK.
Berman DS; Department of Imaging (Division of Nuclear Medicine), Medicine, and Biomedical Sciences, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, USA.
Źródło:: The British journal of radiology [Br J Radiol] 2020 Sep 01; Vol. 93 (1113), pp. 20190797. Date of Electronic Publication: 2019 Dec 19.
Typ publikacji:: Journal Article; Review
Język:: English
Imprint Name(s):: Original Publication: London, British Institute of Radiology.
MeSH Terms:: Fluorine Radioisotopes*/pharmacokinetics
Radiopharmaceuticals*/pharmacokinetics
Sodium Radioisotopes*/pharmacokinetics
Coronary Artery Disease/*diagnostic imaging
Plaque, Atherosclerotic/*diagnostic imaging
Positron-Emission Tomography/*methods
Vascular Calcification/*diagnostic imaging
Computed Tomography Angiography ; Coronary Artery Disease/metabolism ; Humans ; Movement ; Organ Motion ; Plaque, Atherosclerotic/metabolism ; Positron Emission Tomography Computed Tomography ; Risk Factors ; Sodium Fluoride/pharmacokinetics ; Vascular Calcification/metabolism
References:: Am Heart J. 2007 Dec;154(6):1191-8. (PMID: 18035094)
J Nucl Med. 2015 Jul;56(7):1019-23. (PMID: 25952737)
Circ Cardiovasc Imaging. 2017 Mar;10(3):. (PMID: 28292859)
Z Kardiol. 2000;89 Suppl 2:49-53. (PMID: 10769403)
J Nucl Med. 2010 Jun;51(6):862-5. (PMID: 20484438)
Eur Heart J Cardiovasc Imaging. 2020 Jan 1;21(1):58-66. (PMID: 31211387)
J Nucl Med. 2011 Mar;52(3):362-8. (PMID: 21321276)
Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):10741-6. (PMID: 23733926)
JACC Cardiovasc Imaging. 2019 Oct;12(10):2000-2010. (PMID: 30772226)
Cardiovasc Diagn Ther. 2015 Apr;5(2):150-5. (PMID: 25984456)
J Nucl Med. 2016 Jan;57(1):54-9. (PMID: 26471691)
J Nucl Cardiol. 2014 Apr;21(2):293-304. (PMID: 24307262)
Circ Cardiovasc Imaging. 2018 Jan;11(1):e007288. (PMID: 29305350)
Nat Commun. 2015 Jul 07;6:7495. (PMID: 26151378)
J Am Heart Assoc. 2018 Oct 16;7(20):e010224. (PMID: 30371290)
J Nucl Cardiol. 2020 Apr;27(2):494-504. (PMID: 29948889)
Atherosclerosis. 2017 May;260:41-46. (PMID: 28349887)
J Nucl Med. 2019 Apr;60(4):530-535. (PMID: 30213848)
Circulation. 2004 Nov 30;110(22):3424-9. (PMID: 15557374)
Phys Med Biol. 2015 Sep 21;60(18):7127-49. (PMID: 26334312)
Circulation. 2001 Feb 27;103(8):1051-6. (PMID: 11222465)
Curr Opin Lipidol. 2014 Oct;25(5):327-32. (PMID: 25188916)
JAMA Cardiol. 2018 Feb 1;3(2):144-152. (PMID: 29322167)
Circulation. 2015 Jan 27;131(4):e29-322. (PMID: 25520374)
J Nucl Med. 2015 Oct;56(10):1534-40. (PMID: 26205304)
JACC Cardiovasc Imaging. 2016 May;9(5):627-8. (PMID: 26189122)
Arterioscler Thromb Vasc Biol. 2000 May;20(5):1262-75. (PMID: 10807742)
J Nucl Med. 2005 Mar;46(3):424-8. (PMID: 15750154)
Circulation. 1997 Nov 4;96(9):3233-9. (PMID: 9386197)
J Am Coll Cardiol. 2012 Apr 24;59(17):1539-48. (PMID: 22516444)
Semin Nucl Med. 1972 Jan;2(1):31-7. (PMID: 5059349)
Curr Cardiol Rep. 2013 Jun;15(6):364. (PMID: 23605466)
J Am Coll Cardiol. 2015 Jul 28;66(4):337-46. (PMID: 26205589)
Lancet. 2014 Feb 22;383(9918):674-5. (PMID: 24225000)
J Nucl Med. 2019 Jun;60(6):830-836. (PMID: 30442755)
Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):249-258. (PMID: 27796543)
Circ Cardiovasc Imaging. 2018 Jan;11(1):e006973. (PMID: 29305348)
Circ Cardiovasc Imaging. 2017 Nov;10(11):. (PMID: 29133478)
Lancet. 2014 Feb 22;383(9918):705-13. (PMID: 24224999)
J Nucl Cardiol. 2018 Oct;25(5):1742-1756. (PMID: 28176255)
Med Phys. 2009 May;36(5):1775-84. (PMID: 19544796)
Int J Cardiol. 2018 Jan 1;250:278-283. (PMID: 29102056)
J Nucl Med. 2015 Apr;56(4):552-9. (PMID: 25722452)
Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14678-83. (PMID: 17003118)
Med Phys. 2011 Nov;38(11):6313-26. (PMID: 22047396)
Semin Nucl Med. 2015 Jan;45(1):58-65. (PMID: 25475379)
Circ Cardiovasc Imaging. 2019 Jan;12(1):e007835. (PMID: 30642216)
J Am Coll Cardiol. 2006 Apr 18;47(8 Suppl):C13-8. (PMID: 16631505)
J Am Coll Cardiol. 2013 Mar 12;61(10):1041-51. (PMID: 23473409)
Circ Cardiovasc Imaging. 2018 Dec;11(12):e008325. (PMID: 30558496)
IEEE Trans Med Imaging. 2006 Mar;25(3):369-75. (PMID: 16524092)
Grant Information:: RG/16/10/32375 United Kingdom BHF_ British Heart Foundation; FS/14/78/31020 United Kingdom BHF_ British Heart Foundation; CH/09/002/26360 United Kingdom BHF_ British Heart Foundation; R01 HL135557 United States HL NHLBI NIH HHS; G0701127 United Kingdom MRC_ Medical Research Council; United Kingdom WT_ Wellcome Trust
Substance Nomenclature:: 0 (Fluorine Radioisotopes)
0 (Radiopharmaceuticals)
0 (Sodium Radioisotopes)
8ZYQ1474W7 (Sodium Fluoride)
GZ5I74KB8G (Fluorine-18)
Entry Date(s):: Date Created: 20191206 Date Completed: 20200828 Latest Revision: 20220323
Update Code:: 20240104
PubMed Central ID:: PMC7465847
DOI:: 10.1259/bjr.20190797
PMID:: 31804143
: Czasopismo naukowe

Full Text Finder

Positron emission tomography (PET) with 18 F-sodium fluoride ( 18 F-NaF) has emerged as a promising non-invasive imaging modality to identify high-risk and ruptured atherosclerotic plaques. By visualizing microcalcification, 18 F-NaF PET holds clinical promise in refining how we evaluate coronary artery disease, shifting our focus from assessing disease burden to atherosclerosis activity. In this review, we provide an overview of studies that have utilized 18 F-NaF PET for imaging atherosclerosis. We discuss the associations between traditional coronary artery disease measures (risk factors) and 18 F-NaF plaque activity. We also present the data on the histological validation as well as show how 18 F-NaF uptake is associated with plaque morphology on intravascular and CT imaging. Finally, we discuss the technical challenges associated with 18 F-NaF coronary PET highlighting recent advances in this area.

Informacja

Vulnerable plaque imaging using 18 F-sodium fluoride positron emission tomography.